吡格列酮对糖尿病合并高尿酸血症患者血尿酸及颈动脉内膜IMT的影响

Effect of pioglitazone on serum uric acid and carotid artery intimal-medial thickness in patients with type 2 diabetes mellitus with hyperuricaemia

目的探讨吡格列酮对2型糖尿病(T2DM)合并高尿酸血症患者血尿酸的影响,以及尿酸水平与颈动脉内膜中层厚度(IMT)的关系。方法将106例T2DM合并高尿酸血症患者分两组治疗,治疗组及对照组均行常规降糖治疗,治疗组加服吡格列酮15 mg/次,1次/d,疗程均为12周;根据治疗前颈动脉超声结果分为正常组、IMT增厚组和斑块组,检测并比较各组血尿酸变化。结果与对照组治疗后比较,治疗组血尿酸明显降低(P<0.01);颈动脉内膜IMT随血尿酸水平升高而增厚。结论高尿酸血症是T2DM大血管病变的危险因素,吡格列酮可降低其血尿酸水平,延缓大血管病变发生。

Objective To observe the effect of pioglitazone on serum uric acid on patients with type 2 diabetes mellitus （T2DM）with hyperuricaemia, discuss the relation between serum uric acid level and carotid artery intimal-medial thickness（IMT）. Methods 106 patients with T2DM complicating hyperuricaemia were divided into two groups： treatment group and control group. Conventional treatments for lowering blood glucose were given to both groups ,The treatment group took pioglitazong 15 mg each time, once a day. The treatment durations in both groups were 12 weeks. Patients were divided into the IMT normal group, IMT accumulation group and atherosclerosis plaque group according to carotid artery IMT before treatment, and the levels of uric acid were detected and compared in three groups. Results The serum uric acid was significantly lower in the treatment group than that in the control group after treatment （ P 〈 0.01 ）. The level of uric acid was positively associated with the carotid artery IMT（P 〈 0.01 ）. Conclusions The hyperuricaemia is a risk factor of macrovascualr complications in T2DM, pioglitazone can reduce serum uric acid level in patients with T2DM complicating.